[High intensity focalized ultrasound for the treatment of localized prostate cancer]

Haute Autorité de Santé
Record ID 32016000277
French
Authors' objectives: To evaluate the clinical effectiveness of high intensity focalized ultrasound (HIFU) therapy for early localized prostate cancer. HIFU therapy is applied as primary treatment for low and intermediate risk localized prostate cancer (T1-2 NxM0) in patients older than 70 years, and for local recurrence of prostate cancer after radiotherapy failure.
Authors' recommendations: Owing to the poor quality of evidence identified (case-series only, and in most cases a short term follow-up), it is not currently possible to give a firm answer to the question: Are the advantages of HIFU sufficient to counterbalance the complications and uncertainty of results at long term, compared to standard treatment options including either differed (watchful waiting) or immediate (in case of recurrence) hormonal treatment? Adverse events of HIFU therapy mainly affected the urinary tract (postoperative obstruction and infection; long term incontinence), rectum (rectal fistulae) and potency (impotence).
Details
Project Status: Completed
Year Published: 2010
URL for published report: http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-01/rapport_hifu.pdf
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: France
MeSH Terms
  • Humans
  • High-Energy Shock Waves
  • Male
  • Prostatic Neoplasms
  • High-Intensity Focused Ultrasound Ablation
Contact
Organisation Name: Haute Autorité de Santé
Contact Address: 2 avenue du Stade de France, 93218 Saint-Denis La Plaine Cedex, France. Tel: +33 01 55 93 71 88; Fax: +33 01 55 93 74 35;
Contact Name: has.seap.secretariat@has-sante.fr
Contact Email: has.seap.secretariat@has-sante.fr
Copyright: <p>Haute Autorite de Sante/French National Authority for Health (HAS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.